Menu
Not yet recruiting NCT07551908

Evaluation of the Effect of the Mouthwash on Delicate Gums

No phase Interventional Gingivitis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Mouthwash for delicate gums.
Who it may be relevant to
Registry conditions: Gingivitis. Basic parameters: 18 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Evaluation of the Effect of a Cosmetic Product in Improving Gums Condition in Use Test Under Dentist Control.

Overview

The goal of this study is to learn if a mouthwash works to alleviate gingivitis in adults. It will also learn about the safety of the product. The main question it aims to answer is: • Does the mouthwash help to improve signs of gingivitis? Participants will: * Use mouthwash daily for 4 weeks * Visit the clinic on the established days during 4 weeks for check-ups and evaluation

Interventions

  • Other Mouthwash for delicate gums
    Mouthwash will be used 3 times a day after brushing during 4 weeks.

Primary outcome measures

  • Change from Baseline in Gingival Index Score at 4 weeks [Time frame: From enrolment to the end of use at 4 weeks.]

Eligibility criteria

Inclusion criteria

  • Healthy male and female subjects (with no specific repartition)
  • Subjects of Caucasian ethnicity
  • Subjects aged between 18 and 65 years (extremes included)
  • Subjects clinically showing moderate gums inflammation (gingivitis grade II, in particular all gingival scores for the mean should be between 1.75 and 2.3, according to Löe and Silness gingival scoring system), in particular:
  • 20% of the subjects with localized gingivitis (10-30% of evaluated sites with bleeding)
  • 80% of them with generalized gingivitis (>30% of evaluated sites with bleeding)
  • Subjects with dental plaque (total plaque score at inclusion ≥2)
  • Subjects registered with the national health service
  • Subjects certifying the truthfulness of the personal data disclosed to the Principal Investigator or designated personnel
  • Subjects able to understand the language used in the investigation centre and the information given by the Principal Investigator or designated personnel
  • Subjects able to respect the instructions given by the Principal Investigator or designated personnel as well as able to respect the study constraints and specific requirements
  • Subjects who commit not to change their daily routine or lifestyle during the study
  • Subjects on stable pharmacological therapy (except for the pharmacological therapy in the non-inclusion criteria) for at least one month without any changes expected or planned during the study
  • Subjects informed about the test procedures who have signed a consent form and privacy agreement

Exclusion criteria

  • Subjects who do not meet the inclusion criteria
  • Smokers subjects
  • Subjects planning toothcare during the study period
  • Subjects using dental apparatus or using dental prosthesis, with generalized tooth recession, with presence of caries, with dental abscess or signs of periodontitis (periodontal probing depth >3mm) or active periodontitis
  • Subjects using other dental hygiene products than provided (e.g. dental floss, interdental brushes, mouthwash, etc) during the study period
  • Subjects with any acute, chronic, or progressive disease or condition that may interfere with the study data or that the Principal Investigator considers dangerous to the subject or incompatible with the requirements of the study
  • Subjects participating or planning to participate in other clinical trials
  • Subjects who participated in a similar study without respecting an adequate washout period (at least one month)
  • Subjects that have intolerances or allergies to ingredients of the study product Page 8 of 28 Clinical Study Protocol: EC\_0000149/2026 of 13/03/2026
  • Subjects under pharmacological treatments that are considered incompatible with the study requirement by the Principal Investigator
  • Subjects who are currently using products with the same activity as the study product, or who haven't observed an adequate washout period (at least one month)
  • Subjects admitted to a health or social facility
  • Subjects planning a hospitalization during the study
  • Subjects not able to be contacted in case of emergency
  • Subjects deprived of freedom by administrative or legal decision or under guardianship
  • Subjects who have or have had a history of alcohol or drug addiction
  • Subjects with eating disorders (i.e. bulimia, psychogenic eating disorders, etc.)
  • Subject breastfeeding, pregnant or not willing to take necessary precautions to avoid pregnancy during the study (for the women of childbearing potential).

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Other

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07551908 · IT0001492/26

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗